Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 33

Sort by

Sort Order Select

Journal Articles

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

Blood (2025) 146 (Supplement 1): 4074.

https://doi.org/10.1182/blood-2025-4074

Published: 2025

Journal Articles

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Tingyu Wang, Yuting Yan, Ying Yu, Xiong Wenjie, Rui Lv, Tengteng Yu, Wei LIU, Yan Xu, Weiwei Sui, Wenyang Huang, Shuaishuai Zhang, Qi Wang, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 2124.

https://doi.org/10.1182/blood-2025-2124

Published: 2025

Journal Articles

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Rui Lv, Tingyu Wang, Yuting Yan, Tengteng Yu, Xiong Wenjie, Ying Yu, Qi Wang, Shuaishuai Zhang, Hesong Zou, Shuhui Deng, Yan Xu, Dehui Zou, Liang Huang, Gang An, Lugui Qiu, Shuhua Yi

Blood (2025) 146 (Supplement 1): 5379.

https://doi.org/10.1182/blood-2025-5379

Published: 2025

Journal Articles

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Blood (2025) 146 (Supplement 1): 2299.

https://doi.org/10.1182/blood-2025-2299

Published: 2025

Journal Articles

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL

Yi Wang, Wei LIU, Huimin Liu, Qi Wang, Weiwei Sui, Rui Lv, Lugui Qiu, Dehui Zou

Blood (2025) 146 (Supplement 1): 4545.

https://doi.org/10.1182/blood-2025-4545

Published: 2025

Journal Articles

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

Blood (2025) 146 (Supplement 1): 4015.

https://doi.org/10.1182/blood-2025-4015

Published: 2025

Journal Articles

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Wenqiang Yan, Chenxing DU, Rui Lv, Tengteng Yu, Shuaishuai Zhang, Tingyu Wang, Weiwei Sui, Shuhui Deng, Yan Xu, Shuhua Yi, Dehui Zou, Lu-Gui Qiu, Gang An

Blood (2024) 144 (Supplement 1): 3385.

https://doi.org/10.1182/blood-2024-199913

Published: 2024

Journal Articles

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Wenqiang Yan, Lihui Shi, Jingyu Xu, Lingna Li, Jian Cui, Chenxing DU, Tengteng Yu, Shuaishuai Zhang, Rui Lv, Weiwei Sui, Shuhui Deng, Yan Xu, Dehui Zou, Lu-Gui Qiu, Mu Hao, Gang An

Blood (2024) 144 (Supplement 1): 1932.

https://doi.org/10.1182/blood-2024-199452

Published: 2024

Journal Articles

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

Blood (2023) 142 (Supplement 1): 6864.

https://doi.org/10.1182/blood-2023-184868

Published: 2023

Journal Articles

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

Yanshan Huang, Yuting Yan, Ying Yu, Li Yuxi, Rui Lv, Tingyu Wang, Wenjie Xiong, Qi Wang, Wei Liu, Gang An, Weiwei Sui, Yan Xu, Wenyang Huang, Dehui Zou, Lugui Qiu, Shuhua Yi

Blood (2023) 142 (Supplement 1): 3038.

https://doi.org/10.1182/blood-2023-188881

Published: 2023

Journal Articles

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

Huimin Liu, Hesong Zou, Wei Liu, Wenyang Huang, Shuhui Deng, Rui Lv, Weiwei Sui, Yan Xu, Shuhua Yi, Tingyu Wang, Mingwei Fu, Gang An, Yaozhong Zhao, Lugui Qiu, Dehui Zou

Blood (2022) 140 (Supplement 1): 10585–10586.

https://doi.org/10.1182/blood-2022-163258

Published: 2022

Journal Articles

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Wei Liu, Wenyang Huang, Rui Lv, Huimin Liu, Shuhua Yi, Hong Liu, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 4598–4599.

https://doi.org/10.1182/blood-2022-167104

Published: 2022

Journal Articles

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

Wei Liu, Hesong Zou, Yan Xu, Huimin Liu, Chenxing Du, Rui Lv, Wenyang Huang, Weiwei Sui, Shuhua Yi, Lulu Lv, Lugui Qiu, Jianxiang Wang, Dehui Zou

Blood (2022) 140 (Supplement 1): 7472–7473.

https://doi.org/10.1182/blood-2022-166451

Published: 2022

Journal Articles

The Landscape of Immunoglobulin Heavy Chain Gene Repertoire in Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia

Blood (2021) 138 (Supplement 1): 1346.

https://doi.org/10.1182/blood-2021-149397

Published: 2021

Journal Articles

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Tingyu Wang, Ru Li, Rui Lv, Ying Yu, Jiawen Chen, Wenjie Xiong, Qi Wang, Wei Liu, Wenyang Huang, Weiwei Sui, Gang An, Yan Xu, Dehui Zou, Jianxiang Wang, Lugui Qiu, Shuhua Yi, Yi Wang

Blood (2021) 138 (Supplement 1): 3544.

https://doi.org/10.1182/blood-2021-147114

Published: 2021

Journal Articles

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

Shuhua Yi, MD, Jun Du, Ying Yu, Yang Jiao, Yi Wang, Huijun Wang, Tingyu Wang, Rui Lv, Wei Liu, Wenjie Xiong, PhD, Huimin Liu, Wenyang Huang, Dehui Zou, MD, Gang An, Yaozhong Zhao, Jianxiang Wang, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-139481

Published: 2020

Journal Articles

The Real-Word Treatment Outcome of Symptomatic Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in Chinese Patients

Xiong Wenjie, Shuhua Yi, MD, Tingyu Wang, Huimin Liu, Rui Lv, Wei Liu, Dehui Zou, MD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 41–42.

https://doi.org/10.1182/blood-2020-139145

Published: 2020

Journal Articles

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Shuhua Yi, MD, Wenjie Xiong, Yi Wang, Rui Lv, Li Zengjun, Wei Liu, Tingyu Wang, An Gang, MD, Shuhui Deng, MD, Yan Xu, MD, Weiwei Sui, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4003.

https://doi.org/10.1182/blood-2019-130133

Published: 2019

Journal Articles

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Yuting Yan, Yan Xu, Xuehan Mao, MD, Jiahui Liu, Huishou Fan, Qi Wang, Chenxing Du, Li Zengjun, Shuhua Yi, MD, Rui Lv, Shuhui Deng, MD, Weiwei Sui, Mu Hao, PhD, Yu-Tzu Tai, PhD, Nikhil C. Munshi, MD, Gang An, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 4405.

https://doi.org/10.1182/blood-2019-124096

Published: 2019

Journal Articles

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Wenjie Xiong, Shuhua Yi, MD, Yuting Yan, Zengjun Li, Wei Liu, Rui Lv, Zhen Yu, MD, Dehui Zou, MD, Lugui Qiu, MD PhD

Blood (2019) 134 (Supplement_1): 2566.

https://doi.org/10.1182/blood-2019-129860

Published: 2019

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Equecabtagene autoleucel in patients with relapsed or refractory multiple myeloma: The first real-world data from a single Chinese center

A prospective, single-center, single-arm clinical trial of zanubrutinib monotherapy and zfcg combined therapy was given sequentially for the treatment of primary symptomatic CLL/SLL (Stop Trial)

Preliminary analysis of orelabrutinib combined with obinutuzumab in the treatment of marginal zone lymphoma (Orion Study)

Promising safety and efficacy of equecabtagene autoleucel (eque-cel) followed ASCT in ultra high-risk multiple Myeloma (UHR-MM) patients: primary real world data from a single center

Bispecific antibodies serve as a safe and effective bridging therapy prior to CD19 CAR T-cell therapy/combinational therapy of CD19 CAR-T cell and HDT/ASCT in patients with R/R DLBCL

Serum free light chain escape before IMWG progression: A predictive marker and a therapeutic opportunity

BCMA CAR-T Therapy As First-Line Consolidation Treatment in Transplant-Ineligible Patients with Newly-Diagnosed Multiple Myeloma: An Open Label, Single-Arm, Phase 2 Study (CAREMM-001)

Clinical Implications of Residual Immunophenotypically Normal Plasma Cells within Bone Marrow at Various Disease Stages in Multiple Myeloma

Promising Safety and Efficacy of Trovocabtagene Autoleucel (C-CAR088) Followed ASCT in Ultra High-Risk Multiple Myeloma (UHR-MM) Patients Who Failed or Had Suboptimal Response to Standard First Line Triplet Based Therapy

The Prognostic Impact of Measurable Residual Disease Dynamics in Mantle Cell Lymphoma

A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin's Lymphoma

CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study

Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial

The Landscape of Immunoglobulin Heavy Chain Gene Repertoire in Lymphoplasmacytic Lymphoma / Waldenström Macroglobulinemia

Rituximab Maintenance Benefits Less for Follicular Lymphoma Patients with Low Risk of the Follicular Lymphoma International Index

Thalidomide Plus Prednisone and Methotrexate for Symptomatic Large Granular Lymphocyte Leukemia: A Prospective, Single-Center, Pilot Study

The Real-Word Treatment Outcome of Symptomatic Lymphoplasmacytic Lymphoma/ Waldenström Macroglobulinemia in Chinese Patients

Randomized Comparison of Rituximab Versus Bortezomib Plus Cyclophosphamide and Dexamethasone in Newly Diagnosed Waldenstrom Macroglobulinemia Patients

Monitoring the Cytogenetic Architecture of Minimal Residual Plasma Cells Indicates Therapy-Induced Clonal Selection in Multiple Myeloma

Inhibiting the Hippo Signaling Pathway Key Molecule YAP Suppresses Mantle Cell Lymphoma Proliferation By Regulating Multiple Pathogenrelated Signaling Pathways

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only